The Practitioner's Guide to Why Is My Lp(a) Still High?

Why Is My Lp(a) Still High? What the Research Actually Says

You cleaned up your diet. You may be on a statin. Your LDL is cooperating. But your Lp(a) — lipoprotein(a) — remains stubbornly elevated, and your cardiologist or functional medicine practitioner keeps flagging it on every panel. If you've been asking yourself why is my Lp(a) still high, the answer begins with an uncomfortable truth: roughly 70–90% of your Lp(a) level is determined by a single gene, LPA, encoding apolipoprotein(a). No dietary tweak, no supplement, and — notoriously — no standard statin will meaningfully move it for most people (Kamstrup et al., Journal of the American College of Cardiology 2008; PMID: 18206739).

That doesn't mean you're powerless. It means you need a more precise strategy.

---

What Lp(a) Actually Is and Why It's Dangerous

Lp(a) is an LDL-like particle with an additional glycoprotein called apolipoprotein(a) [apo(a)] covalently bound to ApoB-100. This structure makes Lp(a) uniquely atherogenic through three simultaneous mechanisms:

1. Lipid deposition — Lp(a) carries oxidized phospholipids into arterial walls just as LDL does, but with greater affinity.
2. Thrombotic promotion — the apo(a) protein shares structural homology with plasminogen, meaning it competes for clot-dissolving activity and tips the coagulation balance toward clotting.
3. Aortic valve calcification — elevated Lp(a) is one of the strongest independent predictors of calcific aortic stenosis, independent of LDL or total cholesterol (Thanassoulis et al., New England Journal of Medicine 2013; PMID: 23388002).

Clinical thresholds matter here. Most U.S. guidelines flag concern above 75 nmol/L (approximately 30 mg/dL), while the European Atherosclerosis Society places the high-risk cutoff at ≥125 nmol/L (50 mg/dL). Know which unit your lab uses — they are not interchangeable.

---

Why Standard Interventions Don't Move Lp(a)

Before addressing what works, it helps to understand why the usual toolkit fails:

• Statins: Most statins modestly raise Lp(a) by 10–20% — likely by upregulating LPA gene transcription as LDL receptors are cleared. This is not a reason to avoid statins if your ApoB or LDL-C warrants them, but it does mean you cannot rely on statin therapy to address your Lp(a).
• Dietary fat reduction: Because Lp(a) is primarily genetically set, reducing saturated fat has little to no reproducible impact on Lp(a) concentrations in large cohort studies.
• Exercise: Aerobic training does not consistently lower Lp(a), though it reduces overall cardiovascular risk through other pathways.
• Weight loss: Unlike triglycerides or VLDL, Lp(a) is not meaningfully responsive to body weight changes.

This genetic dominance is why seeing an elevated Lp(a) on your panel can feel like a dead end. It isn't — but the levers are different from those you use for LDL or triglycerides.

---

Why Is My ApoB Still High? The Lp(a)–ApoB Connection

If you are asking why is my ApoB still high alongside your Lp(a) concern, pay attention: every Lp(a) particle contains exactly one ApoB-100 molecule. That means elevated Lp(a) contributes directly to your total ApoB particle count — a metric now preferred over LDL-C by many cardiologists for predicting atherogenic risk.

A patient with Lp(a) of 150 nmol/L could have 10–15% of their total ApoB particle burden coming from Lp(a) alone. Lowering Lp(a) will therefore lower ApoB in parallel. Conversely, therapies that reduce ApoB-containing LDL particles (PCSK9 inhibitors, for example) also reduce Lp(a) by 20–30% — making them the only approved drug class with meaningful Lp(a)-lowering effect currently available in clinical practice (Sabatine et al., New England Journal of Medicine 2015; PMID: 26039520).

For a deeper look at the particle-level picture of cardiovascular risk, understanding ApoB and advanced lipid testing is an essential companion topic.

---

Why Is My Triglycerides Still High? A Separate but Related Warning Sign

Lp(a) and elevated triglycerides are independent cardiovascular risk factors that often appear together in metabolic panels flagged by functional medicine practitioners. If you're also asking why is my triglycerides still high, the mechanisms diverge significantly:

Triglycerides respond readily to lifestyle: reducing refined carbohydrate intake, limiting alcohol, increasing omega-3 fatty acids, and improving insulin sensitivity can each cut triglycerides by 20–50%. Unlike Lp(a), triglycerides are largely modifiable.

Omega-3 fatty acids (EPA + DHA) at prescription-strength doses (3.4–4 g/day EPA) have demonstrated 25–33% triglyceride reductions in clinical trials and are FDA-approved for severe hypertriglyceridemia (Bhatt et al., New England Journal of Medicine 2019; PMID: 30415628 — the REDUCE-IT trial). Importantly, omega-3s do not meaningfully lower Lp(a) — reinforcing that the two markers require distinct approaches.

At Ones, omega-3 supplementation is one of the most commonly included actives in formulas flagged for elevated triglycerides or low omega-3 index on bloodwork.

---

What Actually Lowers Lp(a)? The Evidence Hierarchy

Interventions With Strongest Evidence

Nutritional and Supplement Evidence

The supplement literature on Lp(a) is limited but not empty:

• Vitamin C (ascorbic acid): Linus Pauling's early work hypothesized that Lp(a) evolved as a compensatory molecule when primates lost the ability to synthesize vitamin C, and that adequate ascorbate reduces Lp(a) synthesis. While this remains mechanistically plausible, large RCT confirmation is lacking. Small trials suggest modest reductions with high-dose vitamin C (1–3 g/day).
• Niacin (nicotinic acid): High-dose niacin (1.5–3 g/day) lowers Lp(a) by approximately 20–30% in controlled trials, though the cardiovascular outcome benefit over statin therapy alone was not confirmed in the AIM-HIGH trial. Niacin's flush and metabolic side-effect profile limits its use.
• Coenzyme Q10: Does not directly lower Lp(a) but mitigates some downstream oxidative stress associated with elevated Lp(a)-carried oxidized phospholipids.
• L-carnitine: Some evidence for improving the lipid milieu without direct Lp(a) effect.

---

Why Is My Fasting Glucose Still High? The Metabolic–Lp(a) Overlap

If your panel shows both elevated Lp(a) and persistently elevated fasting glucose, you are managing two compounding cardiovascular risks. Interestingly, insulin resistance does not significantly elevate Lp(a) — Lp(a) is largely insulin-insensitive, which is one of the ways it differs from other atherogenic lipoproteins. However, the combination of high Lp(a) and high fasting glucose dramatically amplifies event risk beyond either marker alone.

Asking why is my fasting glucose still high warrants its own investigation: insulin resistance, cortisol dysregulation (which raises hepatic glucose output), inadequate sleep, or micronutrient deficiencies (magnesium, chromium, berberine-responsive pathways) are all addressable. Understanding why fasting glucose stays elevated despite dietary changes is a common frustration that functional blood work can often resolve.

For Lp(a) specifically, optimizing metabolic health through glucose control, while it won't move the Lp(a) number itself, reduces the inflammatory environment in which Lp(a) exerts its most damaging effects.

---

Why Is My A1C Still High? Another Layer of Compounding Risk

A1C reflects 90-day average glucose, and when patients ask why is my A1C still high, it often signals that short-term dietary changes haven't yet been sustained long enough to shift the three-month average — or that stress hormones, sleep disruption, or other factors are overwhelming dietary improvements.

From an Lp(a) perspective, chronic hyperglycemia accelerates glycation of LDL and Lp(a) particles, making them more susceptible to endothelial uptake and oxidative modification. A glycated Lp(a) particle is more dangerous than a non-glycated one. This is a strong argument for treating both markers simultaneously rather than sequentially.

---

The Emerging Frontier: RNA-Targeted Lp(a) Therapies

The most exciting development in Lp(a) medicine is the pipeline of RNA-based therapies targeting LPA gene expression directly:

• Pelacarsen (TQJ230): An antisense oligonucleotide that reduces Lp(a) by 80% in Phase II trials. The Lp(a) HORIZON Phase III cardiovascular outcomes trial is ongoing.
• Olpasiran: An siRNA therapy showing 90%+ Lp(a) reductions in the OCEAN(a)-DOSE trial. Phase III is underway.
• Muvalaplin: A small-molecule oral inhibitor of Lp(a) assembly showing 63–85% reductions in early trials.

These therapies may reach clinical approval within 3–5 years and represent the most significant advance in Lp(a) management in the field's history. Until then, managing cardiovascular risk around elevated Lp(a) remains the primary clinical strategy.

---

What This Means for Your Formula

Lp(a) is one of the few biomarkers where a direct supplement "fix" does not currently exist at the evidence level that warrants confident prescribing. Ones is transparent about this distinction. When the Ones AI reviews a panel showing elevated Lp(a), the response is not to prescribe a phantom Lp(a)-lowering stack — it's to address every modifiable cardiovascular and inflammatory driver that amplifies Lp(a)'s damage:

• Omega-3 (EPA/DHA): Included when triglycerides are elevated, omega-3 index is low, or inflammation markers are raised. At the doses Ones includes, omega-3s address the atherogenic milieu in which Lp(a) operates, reduce VLDL, and lower inflammatory cytokines that worsen endothelial vulnerability to Lp(a) deposition. The REDUCE-IT trial used 4 g/day of icosapentaenoic acid, and Ones calibrates dosing to the individual's omega-3 index from lab data (Bhatt et al., NEJM 2019; PMID: 30415628).

• CoQ10 (Ubiquinol, 200 mg): When statin use is noted in the health history, CoQ10 is commonly included. Statins deplete CoQ10 through mevalonate pathway inhibition, and since statins are the most common co-prescription in high-Lp(a) patients, replenishing CoQ10 supports mitochondrial energy production and antioxidant defense within vascular tissue.

• Ones Heart Support blend: This proprietary System Support combines cardiovascular-relevant actives to address endothelial health and oxidative stress — mechanisms that are particularly relevant when Lp(a)-driven oxidized phospholipid load is high.

For users who upload bloodwork showing combined high Lp(a) + elevated ApoB or triglycerides, Ones builds a formula calibrated to the full lipid picture, not just a single outlier marker.

---

Key Takeaways

• Lp(a) is 70–90% genetically determined — diet and most lifestyle interventions will not meaningfully lower it, and this is not a personal failure.
• Statins do not lower Lp(a) — they may modestly raise it; PCSK9 inhibitors are the only widely available drug class with proven Lp(a)-lowering effect (~20–30%).
• Every Lp(a) particle contains one ApoB molecule, so persistently elevated Lp(a) contributes directly to high ApoB particle count — address both together.
• Omega-3s target triglycerides and inflammation, not Lp(a) directly, but they are still a critical cardiovascular risk management tool when the full lipid panel is elevated.
• Elevated fasting glucose and high A1C amplify Lp(a) risk through glycation and inflammation — managing metabolic health is a parallel priority, not a competing one.
• RNA-targeted therapies (pelacarsen, olpasiran) are in Phase III trials and may represent the first drugs capable of 80–95% Lp(a) reduction — watch this space closely over the next 3–5 years.

Always consult a qualified healthcare provider before making changes to your supplement protocol or cardiovascular medication regimen. Lp(a) management in high-risk individuals often requires specialist-level lipidology input.